Cinven makes second pharma play with new fund
The London-headquartered firm has funded the acquisition of Amdipharm with capital from its fifth fund, which has now reached €4bn as it pursues a €5bn target.
17 January 2013•2 mins read
The London-headquartered firm has funded the acquisition of Amdipharm with capital from its fifth fund, which has now reached €4bn as it pursues a €5bn target.
